Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Halofuginone and muscular dystrophy.

Pines M, Halevy O.

Histol Histopathol. 2011 Jan;26(1):135-46. doi: 10.14670/HH-26.135. Review.

PMID:
21117034
2.

Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone.

Turgeman T, Hagai Y, Huebner K, Jassal DS, Anderson JE, Genin O, Nagler A, Halevy O, Pines M.

Neuromuscul Disord. 2008 Nov;18(11):857-68. doi: 10.1016/j.nmd.2008.06.386. Epub 2008 Jul 30.

PMID:
18672370
3.

Halofuginone inhibits Smad3 phosphorylation via the PI3K/Akt and MAPK/ERK pathways in muscle cells: effect on myotube fusion.

Roffe S, Hagai Y, Pines M, Halevy O.

Exp Cell Res. 2010 Apr 1;316(6):1061-9. doi: 10.1016/j.yexcr.2010.01.003. Epub 2010 Jan 11.

PMID:
20060825
4.

Inhibition of muscle fibrosis and improvement of muscle histopathology in dysferlin knock-out mice treated with halofuginone.

Halevy O, Genin O, Barzilai-Tutsch H, Pima Y, Levi O, Moshe I, Pines M.

Histol Histopathol. 2013 Feb;28(2):211-26. doi: 10.14670/HH-28.211.

PMID:
23275304
5.

Fibrosis inhibition and muscle histopathology improvement in laminin-alpha2-deficient mice.

Nevo Y, Halevy O, Genin O, Moshe I, Turgeman T, Harel M, Biton E, Reif S, Pines M.

Muscle Nerve. 2010 Aug;42(2):218-29. doi: 10.1002/mus.21706.

PMID:
20589893
6.

Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention.

Zion O, Genin O, Kawada N, Yoshizato K, Roffe S, Nagler A, Iovanna JL, Halevy O, Pines M.

Pancreas. 2009 May;38(4):427-35. doi: 10.1097/MPA.0b013e3181967670.

PMID:
19188864
7.

Halofuginone promotes satellite cell activation and survival in muscular dystrophies.

Barzilai-Tutsch H, Bodanovsky A, Maimon H, Pines M, Halevy O.

Biochim Biophys Acta. 2016 Jan;1862(1):1-11. doi: 10.1016/j.bbadis.2015.10.007. Epub 2015 Oct 8.

8.

Halofuginone improves muscle-cell survival in muscular dystrophies.

Bodanovsky A, Guttman N, Barzilai-Tutsch H, Genin O, Levy O, Pines M, Halevy O.

Biochim Biophys Acta. 2014 Jul;1843(7):1339-47. doi: 10.1016/j.bbamcr.2014.03.025. Epub 2014 Apr 2.

9.

Gene expression during chemically induced liver fibrosis: effect of halofuginone on TGF-beta signaling.

Gnainsky Y, Kushnirsky Z, Bilu G, Hagai Y, Genina O, Volpin H, Bruck R, Spira G, Nagler A, Kawada N, Yoshizato K, Reinhardt DP, Libermann TA, Pines M.

Cell Tissue Res. 2007 Apr;328(1):153-66. Epub 2006 Dec 19.

PMID:
17180598
10.

Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone.

Huebner KD, Jassal DS, Halevy O, Pines M, Anderson JE.

Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1550-61. doi: 10.1152/ajpheart.01253.2007. Epub 2008 Feb 8.

11.

Transforming growth factor type-β inhibits Mas receptor expression in fibroblasts but not in myoblasts or differentiated myotubes; Relevance to fibrosis associated to muscular dystrophies.

Cofre C, Acuña MJ, Contreras O, Morales MG, Riquelme C, Cabello-Verrugio C, Brandan E.

Biofactors. 2015 Mar-Apr;41(2):111-20. doi: 10.1002/biof.1208. Epub 2015 Mar 23. Erratum in: Biofactors. 2015 May 6;41(3):209.

PMID:
25809912
13.

Deletion of periostin reduces muscular dystrophy and fibrosis in mice by modulating the transforming growth factor-β pathway.

Lorts A, Schwanekamp JA, Baudino TA, McNally EM, Molkentin JD.

Proc Natl Acad Sci U S A. 2012 Jul 3;109(27):10978-83. doi: 10.1073/pnas.1204708109. Epub 2012 Jun 18.

14.

Focusing on fibrosis: halofuginone-induced functional improvement in the mdx mouse model of Duchenne muscular dystrophy.

McLoon LK.

Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1505-7. doi: 10.1152/ajpheart.00176.2008. Epub 2008 Feb 29. No abstract available.

15.

Elevated Expression of Moesin in Muscular Dystrophies.

Pines M, Levi O, Genin O, Lavy A, Angelini C, Allamand V, Halevy O.

Am J Pathol. 2017 Mar;187(3):654-664. doi: 10.1016/j.ajpath.2016.11.013. Epub 2017 Jan 9.

PMID:
28082118
16.

The role of halofuginone in fibrosis: more to be explored?

Luo Y, Xie X, Luo D, Wang Y, Gao Y.

J Leukoc Biol. 2017 Dec;102(6):1333-1345. doi: 10.1189/jlb.3RU0417-148RR. Epub 2017 Oct 6. Review.

PMID:
28986385
17.

Hydroxy group requirement for halofuginone-dependent inhibition of muscle fibrosis and improvement of histopathology in the mdx mouse model for Duchenne muscular dystrophy.

Wellner G, Mordechay S, Evans P, Genin O, Pines M, Halevy O.

Histol Histopathol. 2019 Jan 10:18083. doi: 10.14670/HH-18-083. [Epub ahead of print]

PMID:
30628720
18.
19.

The involvement of collagen triple helix repeat containing 1 in muscular dystrophies.

Spector I, Zilberstein Y, Lavy A, Genin O, Barzilai-Tutsch H, Bodanovsky A, Halevy O, Pines M.

Am J Pathol. 2013 Mar;182(3):905-16. doi: 10.1016/j.ajpath.2012.11.004. Epub 2012 Dec 27.

PMID:
23274062
20.

Excess SMAD signaling contributes to heart and muscle dysfunction in muscular dystrophy.

Goldstein JA, Bogdanovich S, Beiriger A, Wren LM, Rossi AE, Gao QQ, Gardner BB, Earley JU, Molkentin JD, McNally EM.

Hum Mol Genet. 2014 Dec 20;23(25):6722-31. doi: 10.1093/hmg/ddu390. Epub 2014 Jul 28.

Supplemental Content

Support Center